Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus salivarius WB21
- Development stage
- Phase 1
- Lead developer
- Wakamoto
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus salivarius WB21 is a specific probiotic strain of lactic acid bacteria, recently reclassified taxonomically as Ligilactobacillus salivarius WB21, primarily utilized for the maintenance and improvement of oral health. Developed by Wakamoto Pharmaceutical, this strain is designed to colonize the oral cavity and exert antagonistic effects against common periodontal pathogens, including Porphyromonas gingivalis, Prevotella intermedia, and Aggregatibacter actinomycetemcomitans. The mechanism of action involves competitive exclusion for adhesion sites on oral surfaces and the production of antimicrobial substances such as lactic acid, which lowers the local pH and inhibits the growth of volatile sulfur compound (VSC)-producing bacteria. Clinical evidence suggests that regular consumption of WB21 in lozenge or tablet form can significantly reduce oral malodor (halitosis), decrease plaque accumulation, and improve clinical parameters of periodontitis, such as probing pocket depth and bleeding on probing.
- Brand names
- Avancé
- Other names
- Lactobacillus salivarius strain WB21Ligilactobacillus salivarius WB21
Beyond the preview
Go deeper on Lactobacillus salivarius WB21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus salivarius WB21.